SB54: Bill Text

SB54,3,15 961.14 (4) (tb) Cannabicyclohexonal: 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol.

SB54, s. 5 Section 5. 961.14 (4) (te) of the statutes is created to read:

SB54,3,18 961.14 (4) (te) CP47,497 and homologues: 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol.

SB54, s. 6 Section 6. 961.14 (4) (th) of the statutes is created to read:

SB54,3,24 961.14 (4) (th) HU-210: [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c]chromen-1-o1)], also known as (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6- dimethyl-6H-dibenzo[b,d]pyran-9-methanol.

SB54, s. 7 Section 7. 961.14 (4) (tL) of the statutes is created to read:

SB54,4,2 961.14 (4) (tL) JWH-018: 1-pentyl-3-(1-naphthoyl)indole, also known as Naphthalen-1-yl-(1-pentylindol-3-yl)methanone.

SB54, s. 8 Section 8. 961.14 (4) (tp) of the statutes is created to read:

SB54,4,5 961.14 (4) (tp) JWH-073): 1-butyl-3-(1-naphthoyl)indole, also known as Naphthalen-1-yl-(1-butylindol-3-yl)methanone.

SB54, s. 9 Section 9. 961.14 (4) (tr) of the statutes is created to read:

SB54,4,8 961.14 (4) (tr) JWH-081: 1-pentyl-3-(4-methoxy-1-naphthoyl)indole, also known as 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone.

SB54, s. 10 Section 10. 961.14 (4) (tu) of the statutes is created to read:

SB54,4,11 961.14 (4) (tu) JWH-200: 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole.

SB54, s. 11 Section 11. 961.14 (4) (ty) of the statutes is created to read:

SB54,4,14 961.14 (4) (ty) JWH-250: 1-pentyl-3-(2-methoxyphenylacetyl)indole, also known as 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone.

SB54, s. 12 Section 12. 961.14 (4) (wgm) of the statutes is created to read:

SB54,4,17 961.14 (4) (wgm) 4-iodo-2,5-dimethoxy-beta-phenylethylamine, commonly known as ""2C-I".

SB54, s. 13 Section 13. 961.14 (4) (x) of the statutes is amended to read:

SB54,4,19 961.14 (4) (x) 4-methoxyamphetamine., commonly known as "PMA."

SB54, s. 14 Section 14. 961.14 (7) (intro.) of the statutes is amended to read:

SB54,4,25 961.14 (7) Stimulants. (intro.) Any material, compound, mixture or preparation which contains any quantity of any of the following substances having a stimulant effect on the central nervous system, including any of their precursors, analogs, salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:

SB54, s. 15 Section 15. 961.14 (7) (m) of the statutes is created to read:

SB54,5,2 961.14 (7) (m) Methylenedioxypyrovalerone, commonly known as "MDPV."

SB54, s. 16 Section 16. 961.14 (7) (n) of the statutes is created to read:

SB54,5,5 961.14 (7) (n) 4-methylmethcathinone, commonly known as "mephedrone" or "4-MMC."

SB54, s. 17 Section 17. 961.41 (1) (e) (intro.) of the statutes is amended to read:

SB54,5,14 961.41 (1) (e) Phencyclidine, amphetamine, methamphetamine, and methcathinone, methylenedioxypyrovalerone, and 4-methylmethcathinone. (intro.) If the person violates this subsection with respect to phencyclidine, amphetamine, methamphetamine, or methcathinone, methylenedioxypyrovalerone, or 4-methylmethcathinone, or a controlled substance analog of phencyclidine, amphetamine, methamphetamine, or methcathinone, methylenedioxypyrovalerone, or 4-methylmethcathinone, and the amount manufactured, distributed, or delivered is:

SB54, s. 18 Section 18. 961.41 (1m) (e) (intro.) of the statutes is amended to read:

SB54,5,23 961.41 (1m) (e) Phencyclidine, amphetamine, methamphetamine, and methcathinone, methylenedioxypyrovalerone, and 4-methylmethcathinone. (intro.) If a person violates this subsection with respect to phencyclidine, amphetamine, methamphetamine, or methcathinone, methylenedioxypyrovalerone, or 4-methylmethcathinone, or a controlled substance analog of phencyclidine, amphetamine, methamphetamine, or methcathinone, methylenedioxypyrovalerone, or 4-methylmethcathinone, and the amount possessed, with intent to manufacture, distribute, or deliver, is:

SB54, s. 19 Section 19. 961.41 (3g) (d) of the statutes is amended to read:

SB54,6,14 961.41 (3g) (d) Certain hallucinogenic and stimulant drugs. If a person possesses or attempts to possess lysergic acid diethylamide, phencyclidine, amphetamine, methcathinone, methylenedioxypyrovalerone, 4-methylmethcathinone, psilocin or psilocybin, or a controlled substance analog of lysergic acid diethylamide, phencyclidine, amphetamine, methcathinone, methylenedioxypyrovalerone, 4-methylmethcathinone, psilocin or psilocybin, the person may be fined not more than $5,000 or imprisoned for not more than one year in the county jail or both upon a first conviction and is guilty of a Class I felony for a 2nd or subsequent offense. For purposes of this paragraph, an offense is considered a 2nd or subsequent offense if, prior to the offender's conviction of the offense, the offender has at any time been convicted of any felony or misdemeanor under this chapter or under any statute of the United States or of any state relating to controlled substances, controlled substance analogs, narcotic drugs, marijuana, or depressant, stimulant, or hallucinogenic drugs.

SB54, s. 20 Section 20. 961.41 (3g) (em) of the statutes is created to read:

SB54,7,2 961.41 (3g) (em) Synthetic cannabinoids. If a person possesses or attempts to possess a controlled substance specified in s. 961.14 (4) (tb) to (ty), or a controlled substance analog of a controlled substance specified in s. 961.14 (4) (tb) to (ty), the person may be fined not more than $1,000 or imprisoned for not more than 6 months or both upon a first conviction and is guilty of a Class I felony for a 2nd or subsequent offense. For purposes of this paragraph, an offense is considered a 2nd or subsequent offense if, prior to the offender's conviction of the offense, the offender has at any time been convicted of any felony or misdemeanor under this chapter or under any statute of the United States or of any state relating to controlled substances, controlled substance analogs, narcotic drugs, marijuana, or depressant, stimulant, or hallucinogenic drugs.

SB54,7,3 (End)